Detecting adverse events in surgery: comparing events detected by the Veterans Health Administration Surgical Quality Improvement Program and the Patient Safety Indicators - 25/03/14
, Ann M. Borzecki, M.D., M.P.H. c, d, Susan Loveland, M.A.T. a, Kathleen Hickson, Ph.D., R.N. c, f, Qi Chen, Ph.D., M.D. a, Sally MacDonald, R.N., M.N. c, Marlena H. Shin, J.D., M.P.H. a, Marisa Cevasco, M.D. e, f, Kamal M.F. Itani, M.D. b, e, f, Amy K. Rosen, Ph.D. a, bAbstract |
Background |
The Patient Safety Indicators (PSIs) use administrative data to screen for select adverse events (AEs). In this study, VA Surgical Quality Improvement Program (VASQIP) chart review data were used as the gold standard to measure the criterion validity of 5 surgical PSIs. Independent chart review was also used to determine reasons for PSI errors.
Methods |
The sensitivity, specificity, and positive predictive value of PSI software version 4.1a were calculated among Veterans Health Administration hospitalizations (2003–2007) reviewed by VASQIP (n = 268,771). Nurses re-reviewed a sample of hospitalizations for which PSI and VASQIP AE detection disagreed.
Results |
Sensitivities ranged from 31% to 68%, specificities from 99.1% to 99.8%, and positive predictive values from 31% to 72%. Reviewers found that coding errors accounted for some PSI-VASQIP disagreement; some disagreement was also the result of differences in AE definitions.
Conclusions |
These results suggest that the PSIs have moderate criterion validity; however, some surgical PSIs detect different AEs than VASQIP. Future research should explore using both methods to evaluate surgical quality.
Le texte complet de cet article est disponible en PDF.Keywords : Veterans Health Administration, VA Surgical Quality Improvement Program, Patient Safety Indicators, Adverse surgical events, Administrative data
Plan
| The authors declare no conflicts of interest. |
Vol 207 - N° 4
P. 584-595 - avril 2014 Retour au numéro
Article précédent
- Pancreas-sparing duodenectomy for gastrointestinal stromal tumor
- Suguru Yamashita, Yoshihiro Sakamoto, Akio Saiura, Junji Yamamoto, Tomoo Kosuge, Taku Aoki, Yasuhiko Sugawara, Kiyoshi Hasegawa, Norihiro Kokudo
- Evaluation of genetic biomarkers for distinguishing benign from malignant thyroid neoplasms
- Sapna Nagar, Samreen Ahmed, Claire Peeples, Nichole Urban, Judy Boura, Bryan Thibodeau, Jan Akervall, George Wilson, Graham Long, Peter Czako
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?